APA (7th ed.) Citation

HC, H., Q, D., L, G., T, G., F, P., D, Y., . . . EA, A. (2026). Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models. Science translational medicine, 18(835), eadq6647. https://doi.org/10.1126/scitranslmed.adq6647

Chicago Style (17th ed.) Citation

HC, Huang, et al. "Kras G12C- and G12D-driven Lung Cancers Differ in Oncogenic Potency, Immunogenicity, and Relapse After Kras Inhibition in Mouse Models." Science Translational Medicine 18, no. 835 (2026): eadq6647. https://doi.org/10.1126/scitranslmed.adq6647.

MLA (9th ed.) Citation

HC, Huang, et al. "Kras G12C- and G12D-driven Lung Cancers Differ in Oncogenic Potency, Immunogenicity, and Relapse After Kras Inhibition in Mouse Models." Science Translational Medicine, vol. 18, no. 835, 2026, p. eadq6647, https://doi.org/10.1126/scitranslmed.adq6647.